Phase II study of weekly 4'-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix : an EORTC Gynaecological Cancer Cooperative Group Study
In this study 24 patients with metastatic cervical cancer were treated with a weekly bolus injection of 4'-epidoxorubicin at a dose of 12.5 mg/m2. All patients were followed until disease progression. Toxicity was generally absent or very mild. Only 1 patient (4%) had a partial remission lasting 23 weeks and 9 patients (38%) had stable disease with a median duration of 13 weeks (range 7-36). 4'-Epidoxorubicin at this dose and schedule is not active in metastatic squamous cell carcinoma of the cervix.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
1992 |
---|---|
Erschienen: |
1992 |
Enthalten in: |
Zur Gesamtaufnahme - volume:29A |
---|---|
Enthalten in: |
European journal of cancer (Oxford, England : 1990) - 29A(1992), 1 vom: 16., Seite 147-8 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
van der Burg, M E [VerfasserIn] |
---|
Themen: |
3Z8479ZZ5X |
---|
Anmerkungen: |
Date Completed 29.12.1992 Date Revised 18.07.2019 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM012602817 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM012602817 | ||
003 | DE-627 | ||
005 | 20231221053039.0 | ||
007 | tu | ||
008 | 231221s1992 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0042.xml |
035 | |a (DE-627)NLM012602817 | ||
035 | |a (NLM)1280152 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a van der Burg, M E |e verfasserin |4 aut | |
245 | 1 | 0 | |a Phase II study of weekly 4'-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix |b an EORTC Gynaecological Cancer Cooperative Group Study |
264 | 1 | |c 1992 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 29.12.1992 | ||
500 | |a Date Revised 18.07.2019 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a In this study 24 patients with metastatic cervical cancer were treated with a weekly bolus injection of 4'-epidoxorubicin at a dose of 12.5 mg/m2. All patients were followed until disease progression. Toxicity was generally absent or very mild. Only 1 patient (4%) had a partial remission lasting 23 weeks and 9 patients (38%) had stable disease with a median duration of 13 weeks (range 7-36). 4'-Epidoxorubicin at this dose and schedule is not active in metastatic squamous cell carcinoma of the cervix | ||
650 | 4 | |a Clinical Trial | |
650 | 4 | |a Clinical Trial, Phase II | |
650 | 4 | |a Journal Article | |
650 | 7 | |a Epirubicin |2 NLM | |
650 | 7 | |a 3Z8479ZZ5X |2 NLM | |
700 | 1 | |a Monfardini, S |e verfasserin |4 aut | |
700 | 1 | |a Guastalla, J P |e verfasserin |4 aut | |
700 | 1 | |a de Oliveira, C |e verfasserin |4 aut | |
700 | 1 | |a Renard, J |e verfasserin |4 aut | |
700 | 1 | |a Vermorken, J B |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t European journal of cancer (Oxford, England : 1990) |d 1991 |g 29A(1992), 1 vom: 16., Seite 147-8 |w (DE-627)NLM012602779 |x 1879-0852 |7 nnns |
773 | 1 | 8 | |g volume:29A |g year:1992 |g number:1 |g day:16 |g pages:147-8 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 29A |j 1992 |e 1 |b 16 |h 147-8 |